Erica Andersen-Nissen
Overview
Explore the profile of Erica Andersen-Nissen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
6573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Miner M, Hatherill M, Mave V, Gray G, Nachman S, Read S, et al.
Lancet HIV
. 2022 Oct;
9(11):e791-e800.
PMID: 36240834
New tuberculosis vaccine candidates that are in the development pipeline need to be studied in people with HIV, who are at high risk of acquiring Mycobacterium tuberculosis infection and tuberculosis...
12.
Dintwe O, De Rosa S, Huang Y, Flach B, Manso B, Carter D, et al.
J Leukoc Biol
. 2022 Jul;
112(5):1167-1181.
PMID: 35866359
The HIV Vaccine Trials Network (HVTN) conducts clinical trials on 4 continents in pursuit of a safe and effective HIV vaccine. Cellular immune responses to vaccination that define vaccine immunogenicity...
13.
Moodie Z, Dintwe O, Sawant S, Grove D, Huang Y, Janes H, et al.
J Infect Dis
. 2022 Jun;
226(2):246-257.
PMID: 35758878
Background: The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates...
14.
Hao Y, Hao S, Andersen-Nissen E, Mauck 3rd W, Zheng S, Butler A, et al.
Cell
. 2021 Jun;
184(13):3573-3587.e29.
PMID: 34062119
The simultaneous measurement of multiple modalities represents an exciting frontier for single-cell genomics and necessitates computational methods that can define cellular states based on multimodal data. Here, we introduce "weighted-nearest...
15.
Andersen-Nissen E, Fiore-Gartland A, Ballweber Fleming L, Carpp L, Naidoo A, Harper M, et al.
PLoS Pathog
. 2021 Mar;
17(3):e1009363.
PMID: 33720973
The pox-protein regimen tested in the RV144 trial is the only vaccine strategy demonstrated to prevent HIV-1 infection. Subsequent analyses identified antibody and cellular immune responses as correlates of risk...
16.
Moodie Z, Walsh S, Laher F, Maganga L, Herce M, Naidoo S, et al.
PLoS Med
. 2020 May;
17(5):e1003117.
PMID: 32442195
Background: DNA plasmids promise a pragmatic alternative to viral vectors for prime-boost HIV-1 vaccines. We evaluated DNA plasmid versus canarypox virus (ALVAC) primes in 2 randomized, double-blind, placebo-controlled trials in...
17.
Bekker L, Dintwe O, Fiore-Gartland A, Middelkoop K, Hutter J, Williams A, et al.
EClinicalMedicine
. 2020 May;
21:100313.
PMID: 32382714
Background: Tuberculosis (TB) remains the leading cause of infectious disease-related death. Recently, a trial of BCG revaccination and vaccination with H4:IC31, a recombinant protein vaccine, in South African adolescents (Aeras...
18.
Dintwe O, Rohith S, Schwedhelm K, McElrath M, Andersen-Nissen E, De Rosa S
Cytometry A
. 2020 Jan;
97(2):199-201.
PMID: 31989802
No abstract available.
19.
Hosseinipour M, Innes C, Naidoo S, Mann P, Hutter J, Ramjee G, et al.
Clin Infect Dis
. 2020 Jan;
72(1):50-60.
PMID: 31900486
Background: The Pox-Protein Public-Private Partnership is performing a suite of trials to evaluate the bivalent subtype C envelope protein (TV1.C and 1086.C glycoprotein 120) vaccine in the context of different...
20.
Maurice N, McElrath M, Andersen-Nissen E, Frahm N, Prlic M
Nat Commun
. 2019 Nov;
10(1):4987.
PMID: 31676770
Bystander activation of memory T cells occurs in the absence of cognate antigen during infections that elicit strong systemic inflammatory responses, which subsequently affect host immune responses. Here we report...